Press Releases

Dec 15, 2021, 12:30 AM
#

AcuraStem (acurastem.com), a patient-based drug discovery platform company developing novel therapeutics for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases, announced the results of extensive preclinical studies on its lead program, AS-202, for ALS patients. The data were presented at the Motor Neuron Disease Association 32nd International Symposium on ALS/MND on December 9, by AcuraStem’s Head of Research, Wen-Hsuan Chang, Ph.D.

» Read more
Dec 6, 2021, 5:01 PM
#

AcuraStem will present posters at the 32nd International Symposium on ALS/MND.

» Read more
Jun 28, 2021, 11:32 AM
#

The CMT Research Foundation today announced it has partnered with AcuraStem, a patient-based drug discovery platform company, and Dr. Alessandra Bolino, to test a new drug to fight  CMT4B1. Dr. Alessandra Bolino, who will lead the research and testing, is a renowned expert in CMT and head of the Human Inherited Neuropathies Unit at the prestigious research hospital Ospedale San Raffaele in Milan. 

» Read more
May 25, 2021, 7:04 PM
#

AcuraStem has received an Amyotrophic Lateral Sclerosis Research Pro-gram (ALSRP) Therapeutic Development Award from the Department of Defense, Congressionally Directed Medical Research Programs (CDMRP) totaling $1 million.

» Read more
Sep 21, 2020, 7:52 AM
#

“We are excited to add our collaborator Dr. Robert Bowser to our advisory board. Bob is a worldwide leader in ALS biomarker development. His expertise will be critical as we look to validate key, CNS-specific, mechanistic biomarkers for our PIKFYVE programs,” said Sam Alworth, co-founder and chief executive officer of AcuraStem.

» Read more